ClinicalTrials.gg
CompletedNCT01383486KEIFER SSTUpdated Oct 15, 2015Results posted

Self Selection Trial of Naproxen Sodium

A Phase 3 interventional study of Naproxen sodium ER (BAYH6689) and Advil in Pain, sponsored by Bayer. Completed at 10 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-15.

Sponsored by Bayer · Phase 3 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
253
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
7th of 25
253 · median 100
Started
2011
with 2 others
Phase 3
5 of 25
none open now
Registered
6th of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one is the 7th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 3, and was the 6th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

A pilot trial to demonstrate that consumers can appropriately select Aleve 24 Hour for their own use based on expected duration of pain greater than 12 hours.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Self Selection Tria
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 12 years of age
  • Report taking at least one dose of Over-the-counter (OTC) analgesic for pain in the past month
  • Able to read and understand English
  • Provide written (subjects 12-17 years of age provide written assent and/or parent or legal guardian provide written consent)
  • Provide contact information

Exclusion criteria

Exclusion Criteria:

  • Have participated in a trial involving OTC analgesics in the last 6 months
  • They or someone else in the household work for a market research company, an advertising agency, a public relations firm, a pharmaceutical company, as a healthcare professional, or as part of a health care practice (eliminated for reasons of confidentiality or increased awareness of drugs and their labels)
  • Have a history of known allergies to Nonsteroidal Antiinflammatory Drugs (NSAIDs) (i.e., naproxen, ibuprofen, acetaminophen, aspirin, etc.)
  • Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
  • Female subjects who have a positive urine pregnancy test or who are breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    Naproxen Sodium ER (BAYH6689) or Advil IR

    Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.

    Drug: Naproxen sodium ER (BAYH6689) · Drug: Advil

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours

    Participants were instructed to select a product for use upon their pain episode and then call a toll-free number for an interview within 30 minutes of the selection decision. Participants who did not call were interviewed after 14 days for data collection. The primary endpoint was derived from 2 variables: 1) number of participants who selected Naproxen Sodium ER and reported expected duration of pain less than or equal to 12 hrs (A); 2) number of participants who selected Naproxen Sodium ER and report expected duration of pain greater than 12 hrs (B). The results was calculated as B/(A+B).

    Time frame: up to 14 days

Secondary outcomes

  1. The Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours

    Time frame: Within 24 hours of their selection decision taken up to 14 days

  2. The Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours

    In addition to the primary outcome measure evaluated for all selection evaluable participants, this secondary outcome was evaluated separately for low literacy participants. Low Literacy Participants are defined as those who had REALM (Rapid Estimate of Adult Literacy in Medicine) score \</= 60 at visit 1.

    Time frame: Up to 14 days

07

Results

Posted Nov 29, 2012

Participant flow

Participant flow — Overall Study
MilestoneNaproxen Sodium ER (BAY H6689) or Advil IR
Started253
Treated237
Completed235
Not completed18
Withdrew: Lost to follow-up10
Withdrew: Incomplete information for analysis2
Withdrew: Did not take any product6

Outcome measures

PrimaryThe Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours

Participants were instructed to select a product for use upon their pain episode and then call a toll-free number for an interview within 30 minutes of the selection decision. Participants who did not call were interviewed after 14 days for data collection. The primary endpoint was derived from 2 variables: 1) number of participants who selected Naproxen Sodium ER and reported expected duration of pain less than or equal to 12 hrs (A); 2) number of participants who selected Naproxen Sodium ER and report expected duration of pain greater than 12 hrs (B). The results was calculated as B/(A+B).

Time frame:
up to 14 days
Reported as:
Number · Percentage of participants
The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours
Percentage of participantsNaproxen Sodium ER (BAY H6689) or Advil IR
The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours72.0 (64.9 to 78.4)
SecondaryThe Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours
Time frame:
Within 24 hours of their selection decision taken up to 14 days
Reported as:
Number · Percentage of participants
The Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours
Percentage of participantsNaproxen Sodium ER (BAY H6689) or Advil IR
The Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours71.5 (63.6 to 78.6)
SecondaryThe Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours

In addition to the primary outcome measure evaluated for all selection evaluable participants, this secondary outcome was evaluated separately for low literacy participants. Low Literacy Participants are defined as those who had REALM (Rapid Estimate of Adult Literacy in Medicine) score \</= 60 at visit 1.

Time frame:
Up to 14 days
Reported as:
Number · Percentage of participants
The Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours
Percentage of participantsNaproxen Sodium ER (BAY H6689) or Advil IR
The Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours64.5 (45.4 to 80.8)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium ER (BAY H6689) or Advil IR—0/237 (0%)14/237 (5.9%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventNaproxen Sodium ER (BAY H6689) or Advil IR
Back painMusculoskeletal and connective tissue disorders2/237
NephrolithiasisRenal and urinary disorders1/237
MyalgiaMusculoskeletal and connective tissue disorders1/237
ToothacheGastrointestinal disorders1/237
HeadacheNervous system disorders1/237
Pain in extremityGeneral disorders1/237
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/237
SomnolenceNervous system disorders1/237
ContusionInjury, poisoning and procedural complications1/237
ArthralgiaMusculoskeletal and connective tissue disorders1/237

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Naproxen Sodium ER (BAY H6689) or Advil IR
Mean51.4 ± 14.3
Gender
Gender(Participants)Naproxen Sodium ER (BAY H6689) or Advil IR
Female119
Male115
08

Study locations

10 sites
  • Anaheim, California 92801, United States
  • Yorba Linda, California 92886, United States
  • Pembroke Pines, Florida 33026, United States
  • Griffin, Georgia 30224, United States
  • Andover, Minnesota 55304, United States
  • Roseville, Minnesota 55113, United States
  • Bountiful, Utah 84010, United States
  • West Jordan, Utah 84088, United States
  • Bellevue, Washington 98007, United States
  • Seattle, Washington 98122, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2011
First posted
Jun 28, 2011
Start
Jul 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Nov 29, 2012
Last update
Oct 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01383486
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 28, 2011
Start date
Jul 2011
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Nov 29, 2012
Last update
Oct 15, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naproxen · Ibuprofen

Start the discussion